License and Collaboration Agreements - Schedule of Payments Allocated to Performance Obligations (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2020 USD ($)
Allocation of transaction price
Upfront cash consideration	$ 175,000
Payment for access rights related to the Company's research and development pipeline	100,000
Premium from Stock Purchase Agreement	90,600
Total transaction price allocated to revenue	365,600
Allocation to performance obligations
Zimberelimab license	55,096
Etrumadenant option	126,960
Domvanalimab option	36,728
Access rights related to the Company's research and development pipeline	137,113
Development and commercialization services for zimberelimab	9,703
Total	$ 365,600